Gufic Biosciences (509079) Q1 24/25 earnings summary

Executive summary

• Indore CapEx project completed validation of two manufacturing lines, with commercial production set for September, aiming to address capacity constraints and support growth in domestic and export markets.

• Q1 FY25 marked by strong business momentum, capacity expansion, and new product launches across divisions, including critical care, fertility, and aesthetic dermatology.

• International business expanded with new registrations in Lithuania and Sri Lanka, targeting 40 countries with over 4,150 products in the pipeline.

• R&D progress includes peptide APIs, dual chamber syringes, and positive preclinical results for Selvax in pancreatic cancer.

• Revenue from operations for the quarter ended June 30, 2024, was ₹20,281.20 lakhs, with total income at ₹20,406.66 lakhs, showing growth compared to the previous quarter and the same quarter last year.

Financial highlights

• Q1 FY25 revenue was INR 202.8 crore, up from INR 195 crore in Q1 FY24 and INR 194.9 crore in Q4 FY24.

• Q1 FY25 EBITDA was INR 37 crore, compared to INR 36.4 crore in Q1 FY24 and INR 35.17 crore in Q4 FY24; EBITDA margin at 18.2%.

• Q1 FY25 profit after tax was INR 20.9 crore, versus INR 20.6 crore in Q1 FY24 and INR 20 crore in Q4 FY24; PAT margin at 10.3%.

• FY24 revenue was ₹806.7 crore, with EBITDA of ₹148.1 crore and PAT of ₹86.1 crore.

• Earnings per share (EPS) for the quarter was ₹2.08, compared to ₹2.00 in the previous quarter and ₹2.13 in the same quarter last year.

Outlook and guidance

• Indore facility expected to reach 30-35% utilization in FY26, ramping up to full capacity by FY28, targeting INR 1,500 crore in annual revenue within four years.

• Margin expansion anticipated due to automation, scale, and cost efficiencies at Indore.

• Export growth expected as EU approval is targeted by year-end, enabling faster tech transfers and new market entries.

• Over 150 products in the pipeline for registration in more than 40 countries, supporting global expansion.

• The company continues to focus on its core pharmaceutical segment and has expanded its subsidiary presence in the UK, Ireland, UAE, and India.